Prevalence and Characterization of Persistent Dyspnea After Hospitalization
Recruiting
- Conditions
- Pulmonary DiseaseDyspnea
- Registration Number
- NCT03798158
- Lead Sponsor
- Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
- Brief Summary
The investigators aim to make an overview of persistent dyspnea at the end of an hospitalization for a respiratory disease using an actual tool, the Multidisciplinary Dyspnea Profile questionnaire.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Age over 18 years old
- Able to respond the questionnaire
- Presenting at admission a dyspnea over 3/10 on numerical analogic scale
- Admitted for a respiratory cause
Exclusion Criteria
- cognitive impairment
- aphasia
- no french-speaking person
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of persistent dyspnea in the end of an hospitalization for a a respiratory disease An average of one week, until the end of the hospitalization
- Secondary Outcome Measures
Name Time Method Outcome of patients with persistent dyspnea after hospitalization 6 months 6 months mortality, incidence of rehospitalization
Characterization of persistent dyspnea using MDP An average of one week, until the end of the hospitalization
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie persistent dyspnea post-hospitalization for respiratory diseases?
Are there specific biomarkers that can predict the persistence of dyspnea in patients with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) following acute exacerbations?
How does the Multidisciplinary Dyspnea Profile questionnaire compare to other dyspnea assessment tools in evaluating post-hospitalization outcomes in pulmonary disease patients?
What are the most effective management strategies for persistent dyspnea in patients recovering from acute respiratory conditions like pneumonia or acute bronchitis?
What are the current therapeutic approaches for managing persistent dyspnea, and how might findings from NCT03798158 influence future treatment guidelines for respiratory disease patients?
Trial Locations
- Locations (1)
ADOREPS
🇫🇷Paris, France
ADOREPS🇫🇷Paris, FranceCapucine MORELOT, MD,PhDContact01 42 16 77 71capucine.morelot@aphp.fr